InflaRx N.V. (IFRX)vsModerna Inc (MRNA)
IFRX
InflaRx N.V.
$2.09
+1.95%
HEALTHCARE · Cap: $337.47M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates -22057322% more annual revenue ($2.23B vs $-10,101). IFRX leads profitability with a 0.0% profit margin vs -141.4%. IFRX earns a higher WallStSmart Score of 38/100 (F).
IFRX
Hold38
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IFRX.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 352965.0%
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IFRX
The strongest argument for IFRX centers on Operating Margin, Debt/Equity, Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : IFRX
The primary concerns for IFRX are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
IFRX profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
IFRX carries more volatility with a beta of 2.52 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
IFRX generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
IFRX scores higher overall (38/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
InflaRx N.V.
HEALTHCARE · BIOTECHNOLOGY · USA
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?